Small Molecule Cocktail DLC79 Suppresses Gliomagenesis by Activating Ascl1 and Remodeling Transcriptome

Area of Science:

• Neuro-oncology
• Pharmacological reprogramming
• Cancer therapy

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis due to invasive growth and treatment resistance.
• While genetic reprogramming of glioma cells exists, pharmacological reprogramming presents a more clinically translatable approach.

Purpose of the Study:

• To identify a pharmacological method for reprogramming human glioma cells into a less malignant phenotype.
• To evaluate the efficacy of this reprogramming strategy in vitro and in vivo.

Main Methods:

• Phenotype-driven screening identified a multi-target small-molecule cocktail (DLC79) comprising DAPT, LDN193189, CHIR99021, I-BET762, and Isx9.
• DLC79's effect on glioma cell identity, transcriptional landscape, and oncogenic properties was assessed.
• In vitro assays measured proliferation, migration, invasion, and clonogenicity.
• A subcutaneous xenograft model evaluated tumor growth and bioluminescence after DLC79 pretreatment.

Main Results:

• DLC79 effectively reprogrammed human glioma cells into neuron-like cells, activating endogenous ASCL1 and remodeling the transcriptional landscape.
• Neuronal markers (MAP2, GAD67) were upregulated, while glial markers were suppressed.
• DLC79 treatment inhibited glioma cell proliferation, migration, invasion, and clonogenicity in vitro.
• In vivo, DLC79 pretreatment reduced tumor bioluminescence by 56% and tumor mass by 47%.

Conclusions:

• Pharmacological reprogramming using DLC79 is a viable strategy to convert malignant glioma cells into a less oncogenic, neuron-like state.
• This approach demonstrates significant anti-glioma activity, suggesting a novel therapeutic paradigm for glioblastoma.